Last $85.23 USD
Change Today -1.15 / -1.33%
Volume 347.8K
HTWR On Other Exchanges
Symbol
Exchange
NASDAQ GS
OTC US
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

heartware international inc (HTWR) Snapshot

Open
$86.41
Previous Close
$86.38
Day High
$88.53
Day Low
$85.02
52 Week High
03/5/14 - $98.00
52 Week Low
12/11/14 - $69.05
Market Cap
1.5B
Average Volume 10 Days
173.7K
EPS TTM
$-1.88
Shares Outstanding
17.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HEARTWARE INTERNATIONAL INC (HTWR)

heartware international inc (HTWR) Related Businessweek News

No Related Businessweek News Found

heartware international inc (HTWR) Details

HeartWare International, Inc., a medical device company, is engaged in developing and manufacturing miniaturized implantable heart pumps or ventricular assist devices (VAD) for the treatment of advanced heart failure in the United States and internationally. The company offers HeartWare Ventricular Assist System, which includes a VAD, or blood pump, patient accessories, and surgical tools designed to provide circulatory support for patients in the advanced stage of heart failure. It is also developing the MVAD, a miniaturized blood pump, intended for chronic heart failure patients; and the SYNERGY Circulatory Support System, a partial support system designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent. In addition, HeartWare International, Inc. collaborates with Dualis MedTech GmbH for the development of an implantable system. The company markets its products directly to cardiac centers and hospitals, as well as through medical device distributors. HeartWare International, Inc. is headquartered in Framingham, Massachusetts.

heartware international inc (HTWR) Top Compensated Officers

Chief Executive Officer, President, Managing ...
Total Annual Compensation: $541.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $324.8K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $331.6K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $329.2K
Senior Vice President of Sales and Marketing
Total Annual Compensation: $300.6K
Compensation as of Fiscal Year 2013.

heartware international inc (HTWR) Key Developments

Heartware International Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014

Heartware International Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced revenue of $73,209,000 compared to $53,054,000 for the same period of 2013. Income from operations was $4,077,000 against loss from operations of $19,496,000 for the same period of last year. Loss before taxes was $1,019,000 against $21,422,000 for the same period of last year. Net loss was $916,000 or a $0.05 loss per basic and diluted share, compared to a $22,048,000 net loss, or a loss of $1.33 per basic and diluted share, in the fourth quarter of 2013. Non-GAAP adjusted net loss was $6,936,000 against $15,216,000 for the same period of last year. Non-GAAP adjusted net loss per basic and diluted share was $0.41 against $0.92 for the same period of last year. Non-GAAP net loss for the fourth quarter of 2014 was $6.9 million, or $0.41 per basic and diluted share, compared to a loss of $15.2 million, or $0.92 per basic and diluted share in the fourth quarter of 2013. For the year, the company announced revenue of $278,420,000 compared to $207,929,000 for the same period of 2013. Loss from operations was $124,000 against loss from operations of $47,546,000 for the same period of last year. Loss before taxes was $18,806,000 against $58,844,000 for the same period of last year. Net loss was $19,366,000 or a $1.14 loss per basic and diluted share, compared to a $59,311,000 net loss, or a loss of $3.69 per basic and diluted share, a year ago. Non-GAAP adjusted net loss was $34,576,000 against $51,917,000 for the same period of last year. Non-GAAP adjusted net loss per basic and diluted share was $2.03 against $3.23 for the same period of last year. Non-GAAP net loss for 2014 was $34.6 million, or $2.03 per basic and diluted share, compared to a loss of $51.9 million, or $3.23 per basic and diluted share, in 2013.

Heartware International Inc. Recalls Certain Older Heartware Clinical Trial Controllers

HeartWare International Inc. announced that its is issuing a voluntary Urgent Medical Device Recall in the United States related to older HeartWare® Ventricular Assist System Controllers, which were distributed in the U.S. during the clinical trial period prior to Food and Drug Administration (FDA) approval in 2012. HeartWare has commenced this field action in other countries in recent weeks. In letters to clinicians and patients, the company advises that affected clinical trial controllers exhibit a higher susceptibility to electrostatic discharge (ESD) than newer, commercial controllers. An ESD event could result in a pump stop, which could cause serious injury or death. Since HeartWare has made design enhancements to the newer, commercial controllers to improve immunity to ESD, this recall does not affect newer, commercial controllers. This recall of HeartWare controllers (product codes 1400 and 1401XX) distributed during the ADVANCE and ENDURANCE clinical trial periods with Serial Numbers CON000001 through CON005472 is an expansion of HeartWare's voluntary Field Safety Corrective Action, FSCA APR2013. HeartWare estimates the recall will impact approximately 120 patients in the U.S. As part of the 2013 Notice, HeartWare provided information to assist clinicians and patients in monitoring controller performance and reducing the potential for an ESD event, which is a known risk for electronic equipment. As stated in the 2013 Notice, patients can reduce the risk of ESD by avoiding dry environments, certain fabrics and materials such as silk clothing and carpeting, electronic devices prone to static electricity and certain activities such as vacuuming and removing clothes from a dryer. Since the 2013 Notice, HeartWare has received reports of one additional death and one additional serious injury in which ESD may have caused or contributed to a pump stop.

Heartware International Inc. to Report Q4, 2014 Results on Feb 26, 2015

Heartware International Inc. announced that they will report Q4, 2014 results at 8:00 AM, US Eastern Standard Time on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTWR:US $85.23 USD -1.15

HTWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $60.79 USD -0.21
Getinge AB kr230.50 SEK +9.10
Sunshine Heart Inc $5.75 USD +0.16
Teleflex Inc $121.69 USD +0.47
Thoratec Corp $40.72 USD +0.20
View Industry Companies
 

Industry Analysis

HTWR

Industry Average

Valuation HTWR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEARTWARE INTERNATIONAL INC, please visit www.heartware.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.